News & Videos - RA PHARMACEUTICALS INC.

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face. “At Ra Pharma, our primary focus is the patients and communities we serve. These patients, families, and caregivers are at the core of our effort to develop innovative and...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments. “2019 was a transformational year for Ra Pharma in our efforts to discover, develop, and expand access to important therapies for patients with rare diseases, including the strengthening of our balance sheet with a $150 million financing and the advancement of key clinical and pre-clinical...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology . The JAMA Neurology publication can be accessed here . “This publication in JAMA Neurology recognizes the impact and significance of the findings from our Phase 2 clinical trial demonstrating zilucoplan’s potential in gMG, a chronic and debilitating neuromuscular disease that...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General. “We are pleased that the FDA has authorized the initiation of this...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). “IMNM is a chronic, severe, and debilitating autoimmune disease, and current treatment options are limited and non-specific,” said Andrew Mammen, M.D., Ph.D., Muscle Disease Unit Leader, Laboratory of Muscle Stem Cells and Gene Regulation, and Principal Investigator for the Phase 2 study at the National...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ra Pharmaceuticals, Inc. (NasdaqGM: RARX) to UCB S.A. Under the terms of the proposed transaction, shareholders of Ra will receive only $48.00 in cash for each share of Ra that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company....

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm PR Newswire NEW YORK, Oct. 10, 2019 NEW YORK , Oct. 10, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on behalf of Ra Pharma shareholders concerning the proposed merger with UBC SA. Click...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 10, 2019 NEW YORK , Oct. 10, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Ra Pharmaceuticals, Inc. ("RARX" or the "Company") (NASDAQ: RARX) in connection with the proposed acquisition of the Company by UCB S.A. ("UCB"). Under the terms of the acquisition agreement, RARX shareholders will receive $48.00 for each RARX...

Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price? PR Newswire SAN DIEGO, Oct. 10, 2019 SAN DIEGO , Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra Pharma") breached their fiduciary duties in connection with the proposed sale of the Company to UCB S.A. On October 10, 2019 , Ra Pharma announced that it...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). “In a Phase 2 clinical trial, zilucoplan achieved rapid, clinically meaningful, and statistically significant reductions in primary and key secondary efficacy endpoints, with a durable treatment effect that was sustained at 24 weeks for patients enrolled in the long-term...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS), led by the Sean M. Healey & AMG Center for ALS at Mass General. The Healey Center has agreed to provide funding for the execution of the platform trial to support its goal of accelerating the development of effective treatments for patients with ALS. “The Healey Center brought together...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis (gMG) and other rare, tissue-based complement-mediated diseases. “gMG is a chronic and debilitating neuromuscular disease that affects more...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the Lotte New York Palace, New York, NY. The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website, www.rapharma.com . A replay of the presentation will...